To the Editor, Cytotoxic T lymphocyte antigen-4 (CTLA-4), an inhibitory receptor expressed on T-cells, plays an essential role in regulating immune responses. In healthy individuals, CTLA-4 prevents overstimulation of T-cells and facilitates regulatory T-cell (Treg) suppressive function through competitive binding of CD80/CD86 on antigen-presenting cells. 1 Heterozygous loss-of-function variants in CTLA4 cause the inborn error of immunity (IEI) termed CTLA-4 insufficiency, which has a variable clinical presentation often including combined immunodeficiency, autoimmunity, and lymphoproliferation. 1-3 Since CTLA-4 insufficiency was first described in 2014, over 54 pathogenic variants have been identified. 1,3 Herein, we report two novel CTLA4 variants and describe the clinical presentations in two affected families, the differing functional impacts on CTLA-4mediated transendocytosis, and the influence of prompt access to genetic testing and targeted therapy on clinical outcomes.